Overview

PC-TRiADD’s comprehensive Pharmacology and Drug Design unit helps clients to identify novel drug candidates using methods of computational drug design and cheminformatics, followed by hit-to-lead optimization combined with comprehensive experimental evaluation of pharmacological activity. Our expert team is experienced in both computational and experimental aspects of conventional drug discovery and can seamlessly integrate their services with PC-TRiADD’s other units to provide all the necessary components of focused translational research.

News

Jul 26 2017

Dr. Zoubeidi awarded PCC-Movember Translation Acceleration Grant

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Read more